Health
Amivantamab-chemotherapy demonstrates longest overall survival reported for lung cancer with EGFR mutation
Headline as filed by Medical Xpress.
Compare coverage — 2 reports
| Publisher | Headline | Summary | Published | Detected | Delay | Source | Status |
|---|---|---|---|---|---|---|---|
| Medical Xpress | Amivantamab-chemotherapy demonstrates longest overall survival reported for lung cancer with EGFR mutation |
Results from the phase 3 PAPILLON study show that first-line amivantamab plus carboplatin-pemetrexed (amivantamab-chemotherapy) was associated with numerically longer overall survival compared with ch |
0m | medicalxpress.com | First | ||
| Medical Xpress | Zipalertinib plus chemotherapy significantly extends progression-free survival in first-line EGFR lung cancer |
Adding zipalertinib to platinum-pemetrexed chemotherapy significantly improved progression-free survival in patients receiving first-line treatment for advanced non-small cell lung cancer (NSCLC) harb |
0m | medicalxpress.com | Latest |
Headlines and summaries belong to the publisher named beside them. “Published” is what their feed stated; “detected” is when PageNews first held the report. Delay is measured from the earliest report on this event and describes timing only.
Reader comments
Comments are written by readers. PageNews does not check them and does not stand behind them, and a name here is a name someone typed, not a person we have identified.
Nobody has commented on this story yet.